Items where Author is "Mamot, C."
Number of items: 4. 2015Zaman, K. and Winterhalder, R. and Mamot, C. and Hasler-Strub, U. and Rochlitz, C. and Mueller, A. and Berset, C. and Wiliders, H. and Perey, L. and Rudolf, C. B. and Hawle, H. and Rondeau, S. and Neven, P.. (2015) Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. European Journal of Cancer, 51 (10). pp. 1212-1220. Wicki, A. and Ritschard, R. and Loesch, U. and Deuster, S. and Rochlitz, C. and Mamot, C.. (2015) Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: Production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial. International Journal of Pharmaceutics, 484 (1-2). pp. 8-15. 2012Mamot, C. and Ritschard, R. and Wicki, A. and Kung, W. and Schuller, J. and Herrmann, R. and Rochlitz, C.. (2012) Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. Journal of drug targeting, Vol. 20, H. 5. pp. 422-432. Mamot, C. and Ritschard, R. and Wicki, A. and Stehle, G. and Dieterle, T. and Bubendorf, L. and Hilker, C. and Deuster, S. and Herrmann, R. and Rochlitz, C.. (2012) Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. The Lancet oncology, Vol. 13, H. 12. pp. 1234-1241. |
